SOUTHEAST SIGNAL, INC

Southeast Signal, Inc. specializes in multiple physiological signal amplifiers, with a focus on electroencephalogram (EEG) amplifier systems. These devices are designed to record and amplify brain wave signals, primarily for clinical or research applications. The company’s product line includes examples like the Ochs Labs EEG Amplifier and the Phoenix EEG Amplifier.

Southeast Signal, Inc. is based in the United States, meaning its devices are subject to U.S. medical device regulations. This includes compliance with FDA requirements, though individual devices—not the company—are evaluated for regulatory authorization. The U.S. regulatory framework ensures these products meet safety, performance, and quality standards before use.

Southeast Signal, Inc.’s devices are classified as FDA Class II, which indicates a moderate level of regulatory oversight. Class II devices require special controls beyond general controls to ensure their safety and effectiveness. This classification means the company must follow specific FDA guidelines during design, manufacturing, and post-market surveillance to maintain compliance and device performance.

Yes, Southeast Signal, Inc.’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. The UDI system assigns a unique product identifier to each device, improving tracking, traceability, and transparency in the healthcare system. This listing helps healthcare providers, regulators, and other stakeholders verify device details and compliance status.